![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results |
Yeon Hee Park, Tae Yong Kim, Young-Hyuck Im, Keun-Seok Lee, In Hae Park, Joohyuk Sohn, Soo-Hyeon Lee, Seock-Ah Im, Jee Hyun Kim, Se Hyun Kim, Soo Jung Lee, Su-Jin Koh, Ki Hyeong Lee, Yoon Ji Choi, Eun Kyung Cho, Suee Lee, Seok Yun Kang, Jae Hong Seo, Sung-Bae Kim, Kyung Hae Jung |
Cancer Research and Treatment. 2017;49(2):423-429. Published online 2016 August 3 DOI: https://doi.org/10.4143/crt.2016.191 |
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine Clinical characteristics of Korean breast cancer patients in 1998. The Korean Breast Cancer Society Clinical Characteristics of Breast Cancer Patients in Korea in Year 2000 Pharmacokinetics of Eribulin Mesilate in Combination With Capecitabine in Patients With Advanced/Metastatic Cancer: Results From a Phase Ib Dose-Escalation Study Efficacy and Safety of Eribulin in Patients with Triple Negative Metastatic Breast Cancer: Real Life Experience Mesenchymal Circulating Tumour Cell Analysis to Predict Efficacy of Eribulin for Metastatic Breast Cancer Patients Efficacy and Safety of Eribulin in Patients with HER2-Negative Metastatic Breast Cancer: Real Life Experience Capecitabine/Bevacizumab Compared to Capecitabine Alone in Pretreated Metastatic Breast Cancer: Results of a Phase III Study) Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer |
This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014. |